3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
272
Carcinoma, Non-Small-Cell Lung
195
Prostatic Neoplasms
171
Stomach Neoplasms
100
Lung Neoplasms
93
Squamous Cell Carcinoma of Head and Neck
74
Head and Neck Neoplasms
69
Esophageal Neoplasms
56
Neoplasms
47
Neoplasm Metastasis
36
Pancreatic Neoplasms
31
Nasopharyngeal Carcinoma
30
Ovarian Neoplasms
27
Sarcoma
26
Urinary Bladder Neoplasms
25
Triple Negative Breast Neoplasms
20
Adenocarcinoma
19
Carcinoma, Squamous Cell
17
Adenocarcinoma Of Esophagus
17
Esophageal Squamous Cell Carcinoma
16
Carcinoma, Ovarian Epithelial
15
Unspecified Adult Solid Tumor, Protocol Specific
13
Carcinoma, Transitional Cell
13
Breast Neoplasms, Male
13
Adenocarcinoma of Lung
12
Salivary Gland Neoplasms
11
Laryngeal Neoplasms
11
Small Cell Lung Carcinoma
10
Inflammatory Breast Neoplasms
10
Uterine Cervical Neoplasms
9
Interventions
Capecitabine
6
Irinotecan
5
Fluorouracil
5
Cisplatin
5
Oxaliplatin
4
Leucovorin
4
Gemcitabine
4
apatinib
3
Sorafenib
3
Bevacizumab
3
tislelizumab
2
pembrolizumab
2
Sunitinib
2
Radiotherapy
2
Paclitaxel
2
Immune Checkpoint Inhibitors
2
Cyclophosphamide
2
Cetuximab
2
Aspirin
2
Ascorbic Acid
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
sintilimab
1
regorafenib
1
pyrotinib
1
pemigatinib
1
lutetium Lu 177 dotatate
1
huachansu
1
halofantrine
1
guadecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Digestive System Neoplasms
×
Docetaxel
×
Clear all
NCT05262335
2023-11-28
ALTER-G-001
Ruijin Hospital
Phase 2
Unknown
116 enrolled